4.2 Article

Implications for Multiple Sclerosis in the Era of the Affordable Care Act: An Evolving Treatment Paradigm

Journal

AMERICAN JOURNAL OF MANAGED CARE
Volume 20, Issue 11, Pages S228-S241

Publisher

MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC

Keywords

-

Funding

  1. Biogen Idec
  2. Teva Pharmaceuticals

Ask authors/readers for more resources

The treatment paradigm for multiple sclerosis (MS) continues to evolve as additional pharmacotherapeutic options become available. Furthermore, treatment individualization has become more feasible as new medications with distinct mechanisms of action and improved adverse event profiles have reached the market. As such, clinicians should familiarize themselves with the available treatment options, paying particular attention to their various advantages and disadvantages. In order to offer patients optimal MS therapy, it is crucial for clinicians to stay current with the changing landscape of multiple sclerosis. This article provides a review of the available pharmacotherapeutic options for treating MS, discusses the impact of adherence to therapy, and describes the importance of managing comorbidities often experienced by patients with MS.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available